Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 559 clinical trials
Nivolumab in Combination With Plinabulin in Patients With Metastatic Non-Small Cell Lung Cancer (NSCLC)

The purpose of the study is to determine whether plinabulin (also known as BPI-2358) has an effect on cancer and body in combination with nivolumab, a standard treatment for metastatic squamous

squamous non-small cell lung cancer
tumor cells
measurable disease
metastasis
cancer
  • 0 views
  • 24 Feb, 2021
  • 1 location
BrUOG 379 Phase Ib/II Trial ONC201 + Nivolumab in MSS mCRC

This is a single arm Phase Ib/II, open label, safety, pharmacokinetic, pharmacodynamics and efficacy study of ONC201 in combination with Opdivo (Nivolumab) in adult patients with metastatic

neutrophil count
growth factor
measurable disease
folfirinox
major surgery
  • 0 views
  • 23 Jan, 2021
A Study of E7389 Liposomal Formulation (E7389-LF) Plus Nivolumab in Participants With Solid Tumor

The primary purpose of the study is to evaluate safety and tolerability and to determine recommended Phase 2 dose (RP2D) of E7389-LF in combination with nivolumab in Phase 1b part, and to

  • 2 views
  • 26 Jan, 2021
  • 2 locations
Nivolumab +/- Ipilimumab in Patients With Advanced Refractory Pulmonary or Gastroenteropancreatic Poorly Differentiated Neuroendocrine Tumors (NECs)

> Many Phase III trials showed superiority in terms of efficacy and tolerance of nivolumab+/-ipilimumab versus standard chemotherapy in second-line treatment in metastatic solid tumors

tumor cells
measurable disease
metastasis
neuroendocrine tumor
lung cancer
  • 27 views
  • 26 Jan, 2021
  • 8 locations
Abscopal Effect of Radiotherapy and Nivolumab in Relapsed Hodgkin Lymphoma After Anti-PD1 Therapy

The aim of the trial is to improve efficacy of nivolumab in patients with relapsed or refractory HL who recently progressed on anti-PD1 therapy. Nivolumab is highly effective and well tolerated

nivolumab
lymphoma
avid
  • 4 views
  • 25 Jan, 2021
  • 1 location
18F-PD-L1 PET/CT in Nivolumab Treated Patients With NSCLC

A multicenter single arm biomarker exploration and validation study. Eighty patients with NSCLC that are eligible for first line chemo-immunotherapy, first line nivolumab/ipilimumab or 2nd line

  • 0 views
  • 29 Jan, 2021
  • 8 locations
Immunotherapy With Nivolumab in Combination With Lenvatinib for Advanced Stage Hepatocellular Carcinoma

nivolumab in combination with lenvatinib for patients with multinodular, advanced stage hepatocellular carcinoma in first line therapy

  • 0 views
  • 18 Feb, 2021
  • 1 location
Optune Device - TT Field Plus Nivolumab and Ipilimumab for Melanoma With Brain Metastasis

This phase II study will evaluate the safety of combining intermediate frequency electric field (TT Field) with immunotherapy in melanoma patients with brain metastasis. The data of this study will also inform whether this combination will offer advantage in progression free survival (PFS) and overall survival.

  • 0 views
  • 25 Jan, 2021
  • 1 location
Niraparib + Ipilimumab or Nivolumab in Progression Free Pancreatic Adenocarcinoma After Platinum-Based Chemotherapy

The main purpose of this study is to look at the effectiveness, safety, and anti-tumor activity (preventing growth of the tumor) of the drugs Niraparib with either Ipilimumab or Nivolumab on

cancer
measurable disease
ipilimumab
oxaliplatin
metastasis
  • 23 views
  • 15 Feb, 2021
  • 1 location
Induction Therapy With Vemurafenib and Cobimetinib to Optimize Nivolumab and Ipilimumab Therapy

Rationale The combination of ipilimumab and nivolumab induces relatively high response rates and promising response depth in late stage melanoma. Nevertheless, it

  • 5 views
  • 24 Jan, 2021
  • 13 locations